BioSpace News Archive

A new business intelligence report released by Data Bridge Market Research with title “Bioservices Market Report - Development Trends, Threats, Opportunities and Competitive Landscape” is designed covering micro level of analysis by Key Players and key business segments.

The consistent Clinical Chemistry Market report can be referred efficiently by both established and new players in the Healthcare industry for absolute understanding of the market.

An exceptional Human Identification Market report is a well-known source of information that presents with a telescopic view of the current market trends, situations, opportunities, and status.

Magellan Health, Inc. today announced that Derrick Duke has been appointed chief executive officer, succeeding former CEO Ken Fasola. Fasola has been named the executive vice president, Health Care Enterprises (HCE) at Centene.

RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced preliminary second quarter 2022 net product sales of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, the first and only U.S. Food and Drug Administration (“FDA”)-approved ophthalmic solution for blepharoptosis, or droopy eyelids, of $8.4 million.

Cardinal Health (NYSE: CAH) plans to release fourth-quarter and year-end financial results for its fiscal year 2022 on August 11, prior to the opening of trading on the New York Stock Exchange.

NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that its DERMAdoctor product collections will be featured at Cosmoprof North America, a leading business-to-business (B2B) beauty trade show being held July 12-14 at the Las Vegas Convention Center.

Parkinson Canada in partnership with the Davis Phinney Foundation is excited to launch the first Canadian version of the Every Victory Counts® manual, a comprehensive resource aimed at helping the 100,000 Canadians living with Parkinson’s to maintain and improve their quality of life.

Biohaven Pharmaceutical Holding Company Ltd. today announced that it has commenced enrollment in a Phase 3 clinical trial assessing the efficacy and safety of taldefgrobep alfa in Spinal Muscle Atrophy (SMA).

FDA indicates the Company may proceed with the Phase 3 clinical study of buntanetap for the treatment of Parkinson’s disease.